[Supplementary]Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials

Post time 1 hour(s) ago

journal：Annals of Oncology

Authors：S.-D. Hong; Y.-S. Wang; H.-Y. Zhao; Y.-Y. Zhao; Q.-M. Wang; Y.-X. Ma; Y.-S. Li; Y. Huang; Y.-P. Yang; Z.-M. Fu; L.-K. Chen; F. Zhou; J. Yang; X.-Y. Li; X. Hou; N.-N. Zhou; L.-H. Sun; G.-F. Zhang; J.-W. Cui; L. Wu; G. Chen; Y.-X. Zhang; H.-Y. Wang; D.-Q. Lv; J.-H. Shi; B. Jiang; C. Li; X.-L. Li; K.-J. Tang; Y. Yu; Y.-H. Ji; Z.-Y. He; Y. Zhu; H. Zhu; S. Xiao; C.-C. Zhou; L. Zhang; W.-F. Fang

Published date：2026-6-

DOI：10.1016/j.annonc.2026.01.009

PDF link：https://www.sciencedirect.com/sc ... 923753426000189/pdf

Article link：https://doi.org/10.1016/j.annonc.2026.01.009

Article Source：Elsevier BV。

Remark：

[Elsevier] [Supplementary]Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] [Supplementary]Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials Copy

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] [Supplementary]Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials